High Plasma Phospholipase A2Activity, Inflammation Markers, and LDL Alterations in Obesity With or Without Type 2 Diabetes

Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

(2009) Robert S. Rosenson   CARDIOVASCULAR DRUGS AND THERAPY

Vascular Inflammation, Insulin Resistance, and Reduced Nitric Oxide Production Precede the Onset of Peripheral Insulin Resistance

(2008) Francis Kim et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Biology of Secretory Phospholipase A2

(2008) Boris B. Boyanovsky et al.   CARDIOVASCULAR DRUGS AND THERAPY

Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

(2008) Diana M. Stafforini   CARDIOVASCULAR DRUGS AND THERAPY

Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease

(2008) D. Divchev et al.   EUROPEAN HEART JOURNAL

Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment

(2007) Masanori Iwase et al.   ATHEROSCLEROSIS